Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-alpha and -beta (IFN-alpha/beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-alpha/beta, accompanied by an increase in p53 protein level. IFN-alpha/beta signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-alpha/beta contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In response to senesce-inducing stimuli, senescent cells produce, in a cGAS-dependent manner, type I interferons that have pro-senescence and anti-proliferative activities.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
In the citing paper
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“2a ); ISRE is activated by the IFN-activated transcription factor ISGF3, a heterotrimeric complex consisting of a signal transducer and activator of transcription factor 1 (Stat1), Stat2 and interferon regulatory factor 9 (IRF-9”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Previous studies have shown that p53 -deficient mice show no sign of abnormality in T and B cells, and that they can mount adaptive immune responses normall”
ResultMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024 · cited 1×
“Persistent infection with oncogenic HPV types represents a major risk factor for the development of cervical cancer, in which E6 is known to have a critical role (together with another oncoprotein, E7 (ref”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“We infer that, similar to DNA damage, ATM activation is caused by changes in the chromatin structure in virus-infected cell”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“We also examined the effect of IFN-β on the DNA damage-induced apoptotic response of MEFs expressing the adenovirus E1A oncoprotein, as it is well known that this response is p53-dependent and critical for tumour suppressio”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Self-citation
Research works printed but not linked: 1
- Vilcek, J. & Sen, G. S. in Fields Virology 3rd edn (eds Fields, D. M., Knipe, P. M. & Howley, P. M.) 375–399 (Lippincott-Raven, Philadelphia, 1996)
Cited by
Items 301–400 of 867
Kumar, S., Ingle, H., Mishra, S., Mahla, R. S., Kumar, A., Kawai, T., Akira, S., Takaoka, A., Raut, A. A., & Kumar, H. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.122 · Cited by 45
Self-citationNasirudeen, A. M. A., & Liu, D. X. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21486 · Cited by 45
Type I interferons in the pathogenesis and treatment of canine diseases
Klotz, D., Baumgärtner, W., & Gerhauser, I. (2017) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2017.08.006 · Cited by 47
Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor
Marín-López, A., Calvo-Pinilla, E., Moreno, S., Utrilla-Trigo, S., Nogales, A., Brun, A., Fikrig, E., & Ortego, J. (2019) · Viruses · doi:10.3390/v11010035 · Cited by 48
“Type I IFNs are also important during neurotropic viral infections, where they play multifaceted roles at the blood brain barrier (BBB).”
BackgroundThe Nonstructural NS1 Protein of Influenza Viruses Modulates TP53 Splicing through Host Factor CPSF4
Dubois, J., Traversier, A., Julien, T., Padey, B., Lina, B., Bourdon, J., Marcel, V., Boivin, G., Rosa‐Calatrava, M., & Terrier, O. (2019) · Journal of Virology · doi:10.1128/jvi.02168-18 · Cited by 48
Dubrot, J., Palazón, A., Alfaro, C., Azpilikueta, A., Ochoa, M. C., Rouzaut, A., Martínez‐Forero, I., Teijeira, Á., Berraondo, P., Bon, A. L., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25333 · Cited by 44
The emerging role of interferon regulatory factor 9 in the antiviral host response and beyond
Suprunenko, T., & Hofer, M. J. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.03.002 · Cited by 50
Xie, Y., He, S., & Wang, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.071 · Cited by 45
Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer
Li, R., Zhang, J., Gilbert, S. M., Conejo-Garcia, J. R., & Mulé, J. J. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00483-z · Cited by 45
Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta
Madar, S., Harel, E., Goldstein, I., Stein, Y., Kogan-Sakin, I., Kamer, I., Solomon, H., Dekel, E., Tal, P., Goldfinger, N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061353 · Cited by 42
MacLaine, N. J., Øster, B., Bundgaard, B. B., Fraser, J. A., Buckner, C., Lazo, P. A., Meek, D. W., Höllsberg, P., & Hupp, T. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804433200 · Cited by 44
Interferon-Inducible Protein IFIXα1 Functions as a Negative Regulator of HDM2
Ding, Y., Lee, J.-F., Lu, H., Lee, M.-H., & Yan, D.-H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.5.1979-1996.2006 · Cited by 45
Wan, Q., Wickamarachchi, W. D. N., Whang, I., Lim, B.-S., Oh, M., Jung, S., Kim, H. C., Yeo, S., & Lee, J. (2012) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2012.07.018 · Cited by 44
Li, R., & Wang, L.-X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10743 · Cited by 49
RetractedCoordination of Repair, Checkpoint, and Cell Death Responses to DNA Damage
Wang, J. Y. J., & Cho, S. K. (2004) · Advances in protein chemistry · doi:10.1016/s0065-3233(04)69004-8 · Cited by 46
Ren, M., Gao, L., & Wu, X. (2010) · Immunology & Cell Biology · doi:10.1038/icb.2010.6 · Cited by 42
Childhood asthma and infection: virus-induced exacerbations as determinants and modifiers: Figure 1–
Xepapadaki, P. V., & Papadopoulos, N. G. (2010) · European Respiratory Journal · doi:10.1183/09031936.00149009 · Cited by 47
Inhibition of HIV early replication by the p53 and its downstream gene p21
Shi, B., Sharifi, H. J., DiGrigoli, S., Kinnetz, M., Mellon, K., Hu, W., & de Noronha, C. M. C. (2018) · Virology Journal · doi:10.1186/s12985-018-0959-x · Cited by 45
The Cytidine Deaminase APOBEC3 Family Is Subject to Transcriptional Regulation by p53
Menéndez, D., Nguyen, T., Snipe, J. R., & Resnick, M. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0019 · Cited by 46
Heße, C., Kollenda, S., Rotan, O., Pastille, E., Adamczyk, A., Wenzek, C., Hansen, W., Epple, M., Buer, J., Westendorf, A. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0764 · Cited by 42
Interference with p53 functions in human viral infections, a target for novel antiviral strategies?
Lazo, P. A., & Santos, C. R. (2011) · Reviews in Medical Virology · doi:10.1002/rmv.696 · Cited by 43
Inamura, K., Matsuzaki, Y., Uematsu, N., Honda, A., Tanaka, N., & Uchida, K. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2005.06.003 · Cited by 42
Wakita, D., Chamoto, K., Zhang, Y., Narita, Y., Noguchi, D., Ohnishi, H., Iguchi, T., Sakai, T., Ikeda, H., & Nishimura, T. (2006) · International Immunology · doi:10.1093/intimm/dxh381 · Cited by 42
Meslin, F., Thiery, J., Richon, C., Jalil, A., & Chouaı̈b, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705290200 · Cited by 41
Oncolysis by paramyxoviruses: preclinical and clinical studies
Matveeva, O. V., Guo, Z. S., Senin, V. M., Senina, A. V., Shabalina, S. A., & Chumakov, P. M. (2015) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2015.17 · Cited by 45
The Interaction Between Human Papillomaviruses and the Stromal Microenvironment
Woodby, B. L., Scott, M. L., & Bodily, J. M. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.003 · Cited by 44
Understanding the biosynthesis of platelets‐derived extracellular vesicles
Antwi-Baffour, S. S., Adjei, J. K., Aryeh, C., Kyeremeh, R., Kyei, F., & Seidu, M. A. (2015) · Immunity Inflammation and Disease · doi:10.1002/iid3.66 · Cited by 43
Therapeutic application of RNA interference for hepatitis C virus
Watanabe, T., Umehara, T., & Kohara, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.022 · Cited by 49
Influenza A virus induces p53 accumulation in a biphasic pattern
Yang, S., Wang, X., Guo, L., Qiu, Y., Li, X., Yu, H., Xiang, H., Tong, G., & Ma, Z. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.018 · Cited by 41
IFN-α wakes up sleeping hematopoietic stem cells
Passegué, E., & Ernst, P. (2009) · Nature Medicine · doi:10.1038/nm0609-612 · Cited by 39
Absent in Melanoma 2 proteins in SLE
Choubey, D., & Panchanathan, R. (2017) · Clinical Immunology · doi:10.1016/j.clim.2016.12.011 · Cited by 42
Role of p53 in Regulating Radiation Responses
Okazaki, R. (2022) · Life · doi:10.3390/life12071099 · Cited by 46
Hobom, U., & Dobbelstein, M. (2004) · Journal of Virology · doi:10.1128/jvi.78.14.7685-7697.2004 · Cited by 40
Øster, B., Bundgaard, B. B., & Höllsberg, P. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1961-1965.2005 · Cited by 40
“... cells showed a mobility shift for phosphorylated p53, probably indicating phosphorylation at multiple sites (Fig. 3). Recently, vesicular stomatitis virus and herpes simplex virus were reported to induce ataxia telangiectasia mutated (ATM)-dependent phosphorylation of p53 on Ser18 (corresponding to human Ser15) in…”
BackgroundInfluentialHealthy but not RSV-infected lung epithelial cells profoundly inhibit T cell activation
Wang, H., Su, Z., & Schwarze, J. (2009) · Thorax · doi:10.1136/thx.2007.094870 · Cited by 39
“It has recently been recognised that LECs can contribute to antiviral immune responses. Upon viral infection, LECs express type 1 interferons (IFN) which induce antiviral proteins and LEC apoptosis, activate plasmacytoid DCs and promote cellular antiviral responses,”
BackgroundC/EBPβ Participates in Regulating Transcription of the p53 Gene in Response to Mitogen Stimulation
Boggs, K., & Reisman, D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611675200 · Cited by 43
Human DExD/H RNA helicases: Emerging roles in stress survival regulation
Shih, J.-W., & Lee, Y. W. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.05.003 · Cited by 45
“Since pathogen propagation requires a functional host metabolism, death of host cell could interfere the replicative cycle of pathogens, expose the pathogen to extracellular immune surveillance andpromote activation of adaptive immune system by presenting microbial antigens to T cells [43,44].”
BackgroundYip, H. T., Chopra, R., Chakrabarti, R., Veena, M. S., Ramamurthy, B., Srivatsan, E. S., & Wang, M. B. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.3.317 · Cited by 39
“In a recent report it was shown that the treatment of cells with interferon / increases the expression of p53 and that this expression can be augmented with a chemotherapeutic agent.(40) 1.”
Onabajo, O. O., Porter-Gill, P. A., Paquin, A. R., Rao, N., Liu, L., Tang, W., Brand, N. R., & Prokunina‐Olsson, L. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0161 · Cited by 39
Li, W., Wang, G., Zhang, H., Xin, G., Zhang, D., Zeng, J., Chen, X., Xu, Y., Cui, Y., & Li, K. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.6 · Cited by 38
“18 The expression level and activity of p53 can be substantially increased by treatment with IFN or TNFa”
BackgroundHartmann, S. U., Sid, H., & Rautenschlein, S. (2015) · Avian Pathology · doi:10.1080/03079457.2015.1086974 · Cited by 39
“This observation may explain why aMPV-infected TTOC did not show an increase in the apoptosis rate, as IFN is known to be an inducer of apoptosis (Takaoka et al., 2003).”
BackgroundJin, C. S., Yuan, F., Gu, Y., Li, X., Liu, M., Shen, X., Liu, B., & Zhu, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10774 · Cited by 38
Regulation of Cellular Gene Expression in Endothelial Cells by Sin Nombre and Prospect Hill Viruses
Khaiboullina, S. F., Rizvanov, A. A., Otteson, E. W., Miyazato, A., Maciejewski, J. P., & Jeor, S. S. (2004) · Viral Immunology · doi:10.1089/0882824041310504 · Cited by 42
Alhazmi, M. I., Hasan, T. N., Shafi, G., Alassaf, A. M., Alfawaz, M. A., & Alshatwi, A. A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.22.9655 · Cited by 38
“Caspase-3, -8, and -9 may be the apoptotic effector machinery engaged by p53 to mediate teratogen-induced apoptotic pathways (Takaoka et al., 2003; Pekar et al., 2007).”
BackgroundZwaferink, H., Stockinger, S., Reipert, S., & Decker, T. (2008) · Infection and Immunity · doi:10.1128/iai.01251-07 · Cited by 38
Defective ATM‐p53–mediated apoptotic pathway in multiple sclerosis
Deng, X., Ljunggren‐Rose, A., Maas, K. H., & Sriram, S. (2005) · Annals of Neurology · doi:10.1002/ana.20600 · Cited by 39
Antiviral interferons induced by Newcastle disease virus (NDV) drive a tumor-selective apoptosis
Ginting, T. E., Christian, S., Larasati, Y. O., Suryatenggara, J., Suriapranata, I. M., & Mathew, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-51465-6 · Cited by 37
Viral miRNAs as Active Players and Participants in Tumorigenesis
Gallo, A., Miceli, V., Bulati, M., Iannolo, G., Contino, F., & Conaldi, P. G. (2020) · Cancers · doi:10.3390/cancers12020358 · Cited by 41
“Innate immune signaling shares many key effector proteins with tumor suppressor signaling, such as the p21 cyclin-dependent kinase inhibitor [4] and p53 [5].”
BackgroundType I IFN-mediated regulation of IL-1 production in inflammatory disorders
Ludigs, K., Parfenov, V., Pasquier, R. D., & Guarda, G. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0989-2 · Cited by 41
Activation of NF-kB Pathway by Virus Infection Requires Rb Expression
García, M. Á., Gallego, P. P. F., Campagna, M., González, J., Martinez, G. M., Marcos-Villar, L., Vidal, A., Estéban, M., & Rivas, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006422 · Cited by 41
“Mammalian cells respond to viral infection by producing and secreting type I IFN that triggers the expression or post-translational modification of hundreds of cellular genes some of which are implicated in tumor and viral protective networks”
BackgroundAssociation of Interleukin-12 Polymorphisms and Serum IL-12p40 Levels with Osteosarcoma Risk
Wang, J., Nong, L.-G., Wei, Y., Qin, S., Zhou, Y., & Tang, Y. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.2098 · Cited by 38
Merkel, C. A., Medrano, R. F. V., Baraúna, V. G., & Strauss, B. E. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.23 · Cited by 36
Vareille-Delarbre, M., Kieninger, E., Alves, M. P., Kopf, B. S., Mœller, A., Geiser, T., Johnston, S. L., Edwards, M. R., & Regamey, N. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200405 · Cited by 36
RetractedHuang, Y., Ding, L., Li, Z., Dai, M., Zhao, X., Li, W., Du, Q., Xu, X., & Tong, D. (2013) · Journal of General Virology · doi:10.1099/vir.0.051557-0 · Cited by 36
Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study
Qian, X., Tan, H., Zhang, J., Liu, K., Yang, T., Wang, M., Debinskie, W., Zhao, W., Chan, M. D., & Zhou, X. (2016) · Oncotarget · doi:10.18632/oncotarget.10553 · Cited by 38
Yang, L., Fu, X., Ru, R., Han, B., Zhang, F., Yuan, L., Men, H., Zhang, S., Tian, S., Dong, B., et al. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.02.005 · Cited by 36
Virulence factors in porcine coronaviruses and vaccine design
Zúñiga, S., Pascual‐Iglesias, A., Sánchez, C. M., Sola, I., & Enjuanes, L. (2016) · Virus Research · doi:10.1016/j.virusres.2016.07.003 · Cited by 39
Antiviral activity of doxycycline against vesicular stomatitis virusin vitro
Wu, Z., Wang, X., Wei, J., Li, B., Shao, D., Li, Y., Liu, K., Shi, Y., Zhou, B., Qiu, Y., et al. (2015) · FEMS Microbiology Letters · doi:10.1093/femsle/fnv195 · Cited by 37
“VSV replication was determined by TCID50 assay. p53 is known to inhibit VSV replication (Takaoka et al., 2003).”
BackgroundMethodp53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus
Menéndez, D., Snipe, J. R., Marzec, J. M., Innes, C. L., Polack, F. P., Caballero, M. T., Schurman, S. H., Kleeberger, S. R., & Resnick, M. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128626 · Cited by 36
Rajput, C., Han, M., Ishikawa, T., Lei, J., Goldsmith, A. M., Jazaeri, S., Stroupe, C. C., Bentley, J. K., & Hershenson, M. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.649520 · Cited by 35
“RV-C exposure induced a robust type I and type III interferon response which peaked 48-72 hrs after infection, evidence of viral replication (49).”
BackgroundUka, K., Aikata, H., Takaki, S., Miki, D., Jeong, S. C., Hiramatsu, A., Kodama, H., Shirakawa, H., Kawakami, Y., Takahashi, S., et al. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01554.x · Cited by 35
Apoptosis and immuno-suppression in sheep infected with bluetongue virus serotype-23
Umeshappa, C. S., Singh, K. P., Nanjundappa, R. H., & Pandey, A. B. (2010) · Veterinary Microbiology · doi:10.1016/j.vetmic.2010.02.033 · Cited by 35
Boosting p53 with interferon and viruses
Vilček, J. (2003) · Nature Immunology · doi:10.1038/ni0903-825 · Cited by 35
Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia
Césaire, R., Olière, S., Sharif‐Askari, E., Loignon, M., Lézin, A., Olindo, S., Panelatti, G., Kazanji, M., Aloyz, R. S., Panasci, L. C., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209055 · Cited by 35
“…was about fourfold higher in ATL cells than in activated CD4 cells, further supporting the idea that VSV replication may be influenced by genetic defects unique to tumor cells, including deficiencies in antiviral IFN-a/b and p53 signaling pathways (Stojdl et al., 2000, 2003; Takaoka et al., 2003).”
BackgroundType I interferon and cancer immunoediting
Smyth, M. J. (2005) · Nature Immunology · doi:10.1038/ni0705-646 · Cited by 36
Immunotherapy for gynaecological malignancies
Coukos, G., Conejo-Garcia, J. R., Roden, R. B. S., & Wu, T. ‐. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.9.1193 · Cited by 36
Effect of age on chronic inflammation and responsiveness to bacterial and viral challenges
Elisia, I., Lam, V., Hofs, E., Li, M. Y., Hay, M., Cho, B., Brooks-Wilson, A., Rosin, M., Bu, L., Jia, W., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188881 · Cited by 34
TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense
Wang, L., & Ning, S. (2021) · Viruses · doi:10.3390/v13020279 · Cited by 37
Regulators of G‐protein signalling are modulated by bacterial lipopeptides and lipopolysaccharide
Riekenberg, S., Farhat, K., Debarry, J., Heine, H., Jung, G., Wiesmüller, K., & Ulmer, A. J. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06813.x · Cited by 34
da Silva, L. F., & Jones, C. (2013) · Virus Research · doi:10.1016/j.virusres.2013.04.005 · Cited by 36
“Type I IFN (IFN-α and IFN-β) induction can induce apoptosis (Chawla-Sarkar et al., 2003; Leaman et al., 2002; Takaaoka et al., 2003) or promote cell survival (Yang et al.”
BackgroundViral Organization of Human ProteinsPreprint
Wuchty, S., Siwo, G., & Ferdig, M. T. (2008) · Nature Precedings · doi:10.1038/npre.2008.2041.1 · Cited by 36
Resistance to Rhabdoviridae Infection and Subversion of Antiviral Responses
Blondel, D., Maarifi, G., Nisole, S., & Chelbi‐Alix, M. K. (2015) · Viruses · doi:10.3390/v7072794 · Cited by 38
Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation
Maroui, M. A., Maarifi, G., McManus, F. P., Lamoliatte, F., Thibault, P., & Chelbi‐Alix, M. K. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000447 · Cited by 33
“Previous reports indicated that IFN induced p53-dependent apoptosis (27, 28) and that modification of p53 at K386 by SUMO1 induces p53-dependent transcription (29).”
BackgroundLiu, H., Xue, Y. C., Deng, H., Mohamud, Y., Ng, C. S., Chu, A. J. M., Lim, C. J., Lockwood, W. W., Jia, W. W.-G., & Luo, H. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.01.002 · Cited by 35
“It was shown that TP53 can be transcriptionally activated by type I interferon, a key antiviral mediator, in response to viral infection.(34) Studies have further revealed that p53 contributes to innate immune response through promoting interferonmediated antiviral activity.”
BackgroundThe pros and cons of interferons for oncolytic virotherapy
Geoffroy, K., & Bourgeois‐Daigneault, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.07.002 · Cited by 32
Tumor suppressor p53 regulates intestinal type 2 immunity
Chang, C., Wang, J., Zhao, Y., Liu, J., Yang, X. F., Yue, X., Wang, H., Zhou, F., Inclan-Rico, J. M., Ponessa, J. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23587-x · Cited by 36
Eun, J. R., Lee, H. J., Moon, H. J., Kim, T. N., Kim, J. W., & Chang, J. C. (2009) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365520903367262 · Cited by 33
Ouyang, W., Wang, Y., Meng, K., Pan, Q., Wang, X., Xia, X., Zhu, Y.-M., Bi, Z., Zhang, H., & Luo, K. (2016) · Veterinary Microbiology · doi:10.1016/j.vetmic.2016.12.007 · Cited by 35
Veeranki, S., & Choubey, D. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.06.008 · Cited by 33
Moschonas, A., Ioannou, M., & Eliopoulos, A. G. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200133 · Cited by 32
Xia, Y., Du, Z., Wang, X., & Li, X. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.206 · Cited by 34
Innate immune system activation in zebrafish and cellular models of Diamond Blackfan Anemia
Danilova, N., Wilkes, M. C., Бибикова, Е., Youn, M., Sakamoto, K. M., & Lin, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23561-6 · Cited by 34
Zhu, Z., Du, X., Li, P., Zhang, X., Yang, F., Cao, W., Tian, H. W., Zhang, K., Liu, X., & Zheng, H. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02326 · Cited by 32
“p53-dependent antiviral defense has been widely reported (Takaoka et al., 2003; Shin-Ya et al., 2005; Muñoz-Fontela et al., 2008) .”
BackgroundKim, Y., Lee, D., Lee, J.-H., Lee, S., & Lawler, S. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211041 · Cited by 38
Poly I:C-Induced Tumor Cell Apoptosis Mediated by Pattern-Recognition Receptors
Zhao, X., Ai, M., Guo, Y., Zhou, X., Wang, L., Li, X., & Yao, C. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1226 · Cited by 33
Flaviviruses Are Sensitive to Inhibition of Thymidine Synthesis Pathways
Fischer, M. A., Smith, J. L., Shum, D., Stein, D. A., Parkins, C. J., Bhinder, B., Radu, C., Hirsch, A. J., Djaballah, H., Nelson, J. A., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00101-13 · Cited by 32
Chaperone-Mediated Autophagy in the Liver: Good or Bad?
Dash, S., Aydın, Y., & Moroz, K. (2019) · Cells · doi:10.3390/cells8111308 · Cited by 33
Hasan, T. N., Shafi, G., Syed, N. A., Alfawaz, M. S., Alsaif, M. A., Munshi, A., Lei, K. Y., & Alshatwi, A. A. (2013) · Natural Product Communications · doi:10.1177/1934578x1300800221 · Cited by 32
Interferon regulatory factor 3 activates p53-dependent cell growth inhibition
Kim, T.-K., Lee, J.-S., Jung, J.-E., Oh, S.-Y., Kwak, S., Jin, X., Lee, S.-Y., Lee, J.-B., Chung, Y. G., Choi, Y. K., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.003 · Cited by 34
Activation of innate immunity by mitochondrial dsRNA in mouse cells lacking p53 protein
Wiatrek, D. M., Candela, M. E., Sedmík, J., Oppelt, J., Keegan, L. P., & O’Connell, M. A. (2019) · RNA · doi:10.1261/rna.069625.118 · Cited by 33
“It is also an ISG, induced by IFN upon viral infection (Takaoka et al. 2003).”
BackgroundLee, J.-H., Lee, D., Lawler, S. E., & Kim, Y. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008257 · Cited by 36
“The 34 reverse action of this transformation can be mediated by type I IFN [19,33], which can 35 inhibit tumor growth [36] through regulation of TYK2, JAK1, STAT family, and their 36 downstream pathways [37].”
BackgroundViral and cellular oncogenes promote immune evasion
Roetman, J. J., Apostolova, M. K. I., & Philip, M. (2022) · Oncogene · doi:10.1038/s41388-021-02145-1 · Cited by 34
TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19
Harford, J. B., Kim, S. S., Pirollo, K. F., & Chang, E. H. (2022) · Viruses · doi:10.3390/v14040739 · Cited by 33
The Wheel of p53 Helps to Drive the Immune System
Łasut-Szyszka, B., & Rusin, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087645 · Cited by 32
“The p53 gene was transcriptionally induced by IFNβ, but induction at both the mRNA and protein levels was relatively small (three-fold) [77].”
BackgroundDevelopment and application of oncolytic viruses as the nemesis of tumor cells
Zhu, X. M., Fan, C., Xiong, Z., Chen, M., Li, Z., Tao, T., & Liu, X. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1188526 · Cited by 36
c‐MYC Impairs Immunogenicity of Human B Cells
Schlee, M., Schuhmacher, M., Hölzel, M., Laux, G., & Bornkamm, G. W. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97007-9 · Cited by 32
Okazaki, T., Higuchi, M., Takeda, K., Iwatsuki‐Horimoto, K., Kiso, M., Miyagishi, M., Yanai, H., Kato, A., Yoneyama, M., Fujita, T., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1883 · Cited by 31
Self-citationHunger, A., Medrano, R. F. V., Zanatta, D. B., Valle, P. R. D., Merkel, C. A., Salles, T. A., Ferrari, D. G., Furuya, T. K., Bustos, S. O., Saito, R. D. F., et al. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.17 · Cited by 38
p53 regulates CD46 expression and measles virus infection in myeloma cells
Lok, A., Descamps, G., Tessoulin, B., Chiron, D., Eveillard, M., Godon, C., Bris, Y. L., Vabret, A., Bellanger, C., Maillet, L., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018025106 · Cited by 35
Metadata
- Authors
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., & Taniguchi, T.
- Affiliations
- The University of Tokyo (JP)
- University of Vienna (AT)
- Sapporo Medical University (JP)
- Corresponding author
- Taniguchi, Tadatsugu
- ORCID
- Venue
- Nature
- Published
- 2003-07
- Volume
- 424
- Issue
- 6948
- Pages
- 516-523
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2119885778
- Cited by
- 847
- References
- 51
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 32 · 2020: 41 · 2019: 40 · 2018: 21 · 2017: 38 · 2016: 50 · 2015: 44 · 2014: 40 · 2013: 46 · 2012: 38
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Boehringer Ingelheim Japan
- Senri Life Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, type I interferon, interferon signaling, tumor suppression, antiviral defense, apoptosis, viral infection, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Humans, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Vesicular stomatitis Indiana virus, Signal Transduction, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Interferon-alpha, Interferon-beta, Apoptosis, Response Elements, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.